Heron Q2 revenue $37.7M (+1.3% YoY); withdraws FY2026 guidance on CINVANTI patent loss

HERON THERAPEUTICS, INC. /DE/

2026-Q2 EPS reported -$0.07 revenue$72,377,000

Q2 net revenue $37.7M, up 1.3% YoY; Acute Care up 43.9%, Oncology down 15.9% (CINVANTI -9.7%, SUSTOL -77.5%).
Withdrew FY2026 guidance after Delaware court ruling on CINVANTI patents; paused sales force expansion, considering strategic alternatives.
Amended Hercules Capital credit facility: $13.5M principal reduction at execution, potential $4M more by Sept 15, 2026; covenants reset through 2027.
Cash and investments $42.7M at quarter end; ZYNRELEF net revenue $11.1M (+35% YoY), APONVIE $4.2M (+74% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.